Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects R Rametta, E Mozzi, P Dongiovanni, BM Motta, M Milano, G Roviaro, S Fargion and L Valenti OBJECTIVE: The aim of this study was to evaluate whether dysregulation of molecules involved in FOXO1-dependent insulin signaling in the liver is associated with de novo lipogenesis (DNL) and altered lipid metabolism in severely obese subjects. DESIGN: Observational retrospective study. SUBJECTS: We considered 71 obese subjects (age 20-68 years; body mass index (BMI)440 kg m À 2 or BMI435 kg m À 2 in the presence of metabolic complications) classified into three groups according to liver histology: normal liver (n ¼ 12), simple steatosis (n ¼ 27) and nonalcoholic steatohepatitis (NASH; n ¼ 32). Key nodes in insulin signaling and gene expression of molecules implicated in insulin-dependent glucoregulatory pathway and DNL were evaluated by quantitative real-time PCR and western blotting. RESULTS: Patients with steatosis had decreased phosphorylation of the insulin kinase AKT1, mediating insulin receptor signaling, and the transcription factor FOXO1, which was therefore more active mediating insulin resistance at transcriptional level. Despite no changes in insulin receptor substrate (IRS)1 mRNA levels, the mRNA and protein levels of the FOXO1 target IRS2 increased progressively with the severity of steatosis from normal liver to NASH. IRS2 expression was correlated with the severity of steatosis, dyslipidemia and liver damage. In patients with NASH, upregulation of IRS2 was associated with preserved activation of AKT2, mediating the stimulating effect of insulin on DNL, and overexpression of its target sterol regulatory element-binding protein 1c (SREBP1c), inducing DNL at transcriptional level. Both FOXO1 and SREBP1c overexpression converged on upregulation of glucokinase, providing substrates for DNL, in NASH patients. CONCLUSION: Differential regulation of IRS1 and IRS2 and of their downstream effectors AKT1 and AKT2 is consistent with upregulation of FOXO1 and may justify the paradoxical state of insulin resistance relative to the glucoregulatory pathway and augmented insulin sensitivity of the liporegulatory pathway typical of steatosis and the metabolic syndrome in obese patients.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in western societies, affecting 10-25% of the general population and 50-75% in subjects with obesity, the major risk factor for hepatic lipid accumulation. 1 Obesity is indeed emerging as a global healthcare problem: in a Mediterranean country such as Italy the prevalence of overweight subjects reaches 35%, 10% of whom are morbidly obese. 2, 3 NAFLD includes a wide range of conditions spanning from simple steatosis (SS) to nonalcoholic steatoepatitis (NASH), which may evolve to cirrhosis and hepatocellular carcinoma. 4 NAFLD is considered the hepatic manifestation of the metabolic syndrome, characterized by a cluster of alterations, including glucose intolerance/insulin resistance (IR), and is metabolically characterized by hepatic IR resulting in increased glucose output (HGO) and enhanced de novo lipogenesis (DNL), contributing to the pathogenesis of diabetes and dyslipidemia. 5 During hepatic IR, insulin fails to inactivate FOXO1, which mediates the effect of the hormone at transcriptional level on gluconeogenis, through AKT-dependent phosphorylation. 6 At the same time, hyperinsulinemia promotes DNL from glucose and increased free fatty acids flux to the liver due to peripheral IR through the sterol regulatory element-binding protein-1c (SREBP1c) and inhibits b-oxidation of FA through the nuclear receptor peroxisome proliferators-activated receptor-a (PPARa). The resulting excess of FA is redirected to formation of triglycerides that accumulate causing NAFLD, 7 and to mitochondria leading to free radicals generation, lipoperoxidation and endoplasmic reticulum stress, which activates a response signaling network that drives cytokine-mediated apoptotic and inflammatory reactions, that is, NASH. However, the mechanisms underlying the dissociation between hepatic insulin signaling regulating HGO (inhibited) and DNL (promoted) are still unclear.
Recent work suggested that insulin signaling through different isoforms of insulin receptor substrates (IRS) and of the kinase AKT may have complementary roles in the regulation of hepatic glucose and lipid metabolism, with IRS2 and AKT2 specifically controlling DNL. [8] [9] [10] Interestingly, upregulation of FOXO1 has been suggested to represent a link explaining the differential regulation of the branches of insulin signaling, as it becomes active in the presence of IR, but it induces IRS2 and downregulates potentially selective inhibitors of AKT pathway. [11] [12] [13] However, the bulk of these studies were conducted in animal knockout models with conflicting conclusions related to different backgrounds, feeding conditions and diets, and results were not yet confirmed in human disease.
As we previously showed that in obese patients, a progressive increase in FOXO1 activity related to inhibition of AKT1 with increasing severity of steatosis/NASH is associated with IR, 14,15 the aim of this study was to evaluate whether dysregulation of molecules involved in FOXO1-dependent insulin signaling is associated with DNL and altered lipid metabolism in severely obese patients with a full spectrum of liver pathology, reflecting different degrees of IR. 16 
MATERIALS AND METHODS Subjects
We considered 71 subjects of a larger series of 89 patients who underwent bariatric surgery at the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, between 2006 and 2008, with body mass index (BMI)440 kg m À 2 or BMI435 kg m À 2 in the presence of metabolic complications (type 2 diabetes, uncontrolled hypertension, severe dyslipidemia, obstructive sleep apnea syndrome). We excluded subjects with diabetes or therapies influencing glucose levels (n ¼ 14), alcohol consumption430/20 g per day for M/F (n ¼ 1) and chronic viral hepatitis (n ¼ 3).
Glucose, high-density lipoprotein (HDL) cholesterol, low high-density lipoprotein (LDL) cholesterol, total cholesterol, tryglicerides, alanine aminotransferase and aspartate aminotransferase were assessed on the day of surgery. Routine needle liver biopsy was performed in all patients for histological analysis, and part of the sample was immediately frozen in liquid nitrogen for RNA analysis. Evaluation of protein levels was performed in a subgroup of 24 subjects, for whom enough tissue was available. The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of the Fondazione IRCCS Ca' Granda, and each subject gave written informed consent.
Histological analysis
A single expert pathologist unaware of gene expression data evaluated all biopsies 17 according to Kleiner et al, 18 based on the determination of NAFLD activity score as result of the sum of steatosis severity (0-3), intralobular necroinflammation (0-3) and hepatocellular ballooning (0-2). The percentage of hepatocytes with steatosis was determined in at least 10 hepatic lobules per patient. Subjects were classified in three groups according to liver histology: 32 NASH, 27 SS and 12 controls with histologically normal liver (NL). Demographic and anthropometric data of subjects included are summarized in Table 1 1 5 ± 5 2 4 ± 13 48 ± 28*,*** 0.0001 AST (IU ml À 1 ) 1 5 ± 3 2 0 ± 9 2 9 ± 13*,*** 0.0006 
RESULTS
Clinical and metabolic features associated with NASH As shown in Table 1 , subjects were predominantly females (69%), but a higher prevalence of males was observed in NASH group (P ¼ 0.0065). Age distribution was not significantly different according to liver histology. As expected, BMI and glucose levels were higher in patients with NASH compared with NL (P ¼ 0.02 and P ¼ 0.05, respectively). Aminotransferases were significantly higher in NASH compared with other groups (alanine aminotransferase P ¼ 0.00004 vs NL, and P ¼ 0.0001 vs SS; aspartate aminotransferase P ¼ 0.0006 vs NL, and P ¼ 0.003 vs SS), whereas HDL cholesterol levels, a sensitive marker of hepatic IR and atherogenic dyslipidemia, differed significantly across groups with decreasing levels from NL to SS, to NASH (P ¼ 0.00001 NL vs NASH; P ¼ 0.01 NL vs SS; P ¼ 0.0058 SS vs NASH).
IRS2 expression is associated with NASH and dyslipidemia We first evaluated key steps in the proximal insulin signal cascade. INSR mRNA levels were lower in SS and NASH than in NL (P ¼ 0.004 and P ¼ 0.006, respectively). INSR protein levels did not differ among groups (Table 2 ), but as INSR is regulated through ligand-mediated endocytosis, whole cellular lysates cannot discriminate the IR fraction expressed on cell surface. Although IRS1 levels did not differ among groups, IRS2 mRNA levels increased progressively with the severity of liver histology (Table 2) , with higher values in NASH compared with NL (P ¼ 0.005) and also to SS (P ¼ 0.032). Hepatic IRS2 mRNA was correlated with serum markers of liver damage (aspartate aminotransferase P ¼ 0.0003, alanine aminotransferase P ¼ 0.024, HDL cholesterol P ¼ 0.005), and steatosis severity measured as NASH activity score (NAS, P ¼ 0.0002) as well as with all NAS single components (steatosis P ¼ 0.0004, ballooning P ¼ 0.03, necroinflammation P ¼ 0.004, fibrosis stage P ¼ 0.008, percentage of steatosis P ¼ 0.0009; Supplementary Figure 1) . Importantly, in line with gene expression results, IRS2 protein levels increased progressively with the severity of liver histology (Figure 1 ).
Regulation of AKT and FOXO1 activity
To evaluate the potential relevance of increased IRS2, we analyzed the expression and activity of the two major liver-expressed AKT isoforms (Table 2) . Neither AKT1 nor AKT2 mRNA levels differed among groups. Despite there being no differences among groups neither in total amount of AKT protein levels, 15 there was a progressive reduction of pThr308AKT1/AKT1, reflecting AKT1 activity, in SS and NASH compared with NL (P ¼ 0.009 and P ¼ 0.03, respectively), a nonsignificant trend for decreased pSer473AKT1/AKT1, whereas there was a trend for increased AKT2 activity with worsening of liver disease. Reduced AKT1 activation is consistent with upregulation of FOXO1 protein, a transcriptional inducer of IRS2. [11] [12] [13] Indeed, as previously reported, 15 there was a progressive increase in the levels of unphosphorylated (nuclear and transcriptionally active) FOXO1 from NL to NASH, whereas pSer256FOXO1 to total FOXO1 ratio, reflecting activation status of protein, decreased with increasing severity of liver disease (P ¼ 0.0044 NL vs NASH and P ¼ 0.017 SS vs NASH), consistently with IR ( Figure 1) . The mRNA and protein levels of pseudokinase tribble 3 (TRB3), another FOXO1 target 11 acting as a modulator of AKT activity, were not significantly different according to liver histology (Table 2) . Lipogenesis As AKT2 mediates insulin action on DNL inducing SREBP1c activation, 10, 19, 20 we evaluated lipid metabolism to investigate whether preserved activation of AKT2 supports DNL in NASH. DNL is stimulated by insulin first through glucokinase (GCK) activation. 21, 22 Hepatic GCK mRNA levels were higher in NASH than in NL and SS (P ¼ 0.01 and P ¼ 0.001, respectively; Table 2 ). Similarly, mRNA levels of SREBP1c were higher in NASH compared with both NL and SS (P ¼ 0.035 and P ¼ 0.02, respectively), and was positively correlated with the severity of steatosis (P ¼ 0.013), confirming previous data indicating that SREBP1c is induced by insulin even during profound IR. 23 In contrast, we did not get evidence of increasing unfolded protein response activation, possibly influencing SREBP1c, as detected by mRNA levels of CHOP, GRP78 and XBP-1 (active form) according to liver histology (Table 2 ). SREBP1c regulates DNL inducing the transcription of acetyl-CoA carboxylase 1, fatty acid synthase (FAS) and stearoylCoA desaturase 1 (SCD1), rate-limiting enzymes catalyzing synthesis of FAs, but we did not find significant differences in the expression of these genes according to liver histology, except for a trend to increment in FAS and SCD1 mRNA levels from NL to NASH (Table 2 ). FAS and SCD1 mRNA levels were correlated with GCK expression (P ¼ 0.01 and Po0.0001, respectively).
Lipolysis and lipoprotein export
We finally evaluated the possible involvement of impaired b-oxidation and very low-density lipoprotein (VLDL) secretion in IRS2 and steatosis R Rametta et al the pathogenesis of steatosis. The mRNA levels of PPARa, controlling the expression of enzymes involved in lipid catabolism, such as carnitine palmitoyltransferase-1 (CPT1), were reduced in NASH compared with NL and SS (P ¼ 0.035 and P ¼ 0.05, respectively; Table 2 ). There was a parallel trend for decreasing CPT1 expression from NL to SS and NASH. Both PPARa and CPT1 were inversely correlated to NAS (P ¼ 0.015 and P ¼ 0.032, respectively), the severity of steatosis (P ¼ 0.021 and P ¼ 0.044, respectively) and IRS2 mRNA levels (P ¼ 0.045 and P ¼ 0.029, respectively), suggesting a role for impaired b-oxidation in the pathogenesis of NAFLD. The metabolic imbalance between DNL and FA oxidation, which is well represented by SREBP1c/PPAR-a mRNA content ratio 24 was also increased in NASH compared with SS (P ¼ 0.02). The synthesis and secretion of VLDLs are also regulated by PPARa, and facilitated by microsomal triglyceride transfer protein (MTTP) in a rate-limiting step that is regulated by insulin via FOXO1. 25 MTTP mRNA levels progressively decreased from NL to SS and NASH (P ¼ 0.03), suggesting that reduced MTTP levels contribute to hepatocellular lipid accumulation in NASH ( Table 2 ). The expression of apolipoprotein C3, another FOXO1 target involved in lipoprotein metabolism, 26 was not significantly affected by liver histology (not shown).
DISCUSSION
In this paper, we evaluated whether in severely obese patients selective modulation of hepatic insulin signaling, depending on FOXO1 as a consequence of decreased AKT1 activity and IR, 15, 27 supports DNL. In line with the experimental hypothesis, the expression of IRS2 was associated with the severity of hepatic steatosis and NASH, in the presence of preserved AKT2 activity and induction of SREBP1c and GCK.
NAFLD and obesity are characterized by IR, 28 whose hepatic manifestation is inappropriately high HGO, which we previously linked to increased activity of FOXO1 in NASH, 15 whereas induction of DNL contributing to hepatosteatosis and dyslipidemia more closely resemble a state of augmented insulin sensitivity. This would imply that therapeutic approaches aimed to increase insulin levels would paradoxically favor atherogenic dyslipidemia and liver damage related to NAFLD. A bulk of literature was produced to explain the selective role of insulin signaling molecules in the regulation of glucose and lipid metabolism in various animal models with conflicting results, and without confirmation in humans. Thus, we addressed the regulation of INSR signaling modulators depending on FOXO1 in the liver of severely obese patients with a full spectrum of liver damage.
We preliminary confirmed that in obese patients with NASH reduced Thr308 phosphorylation of AKT1 was associated with reduced phosphorylation of the transcription factor FOXO1, leading to increased level of the active nuclear form. 15, 27, 29 The most striking observation consists in the evidence of a progressive upregulation of IRS2 with increasing severity of steatosis, liver damage and dyslipidemia, all associated with systemic IR in severely obese patients, 16 that paralleled FOXO1 upregulation, 15 and which, to our knowledge, represents a novel finding. Constitutively nuclear FOXO1 induces IRS2, 30 liver-specific deletion of INSR was associated with induction of hepatic IRS2, 31 and hepatic IRS2 expression is upregulated by FOXO1 during prolonged nutrient deprivation, 12, 13 supporting the hypothesis that unblunted FOXO1 activity is responsible for IRS2 induction. Interestingly, IRS1 did not change with steatosis; this pattern is reminiscent of the upregulation of IRS2 by FOXO1, which surpasses IRS1 levels during prolonged fasting, providing a mechanism to handle the transition from fasting to refeeding state to quickly respond to insulin level fluctuations. 32 Therefore, upregulation of IRS2 by unrestricted FOXO1 in NAFLD could represent a permissive mechanism linking hyperinsulinemia with induction of DNL even during fasting. 33, 34 This view is further supported by the downstream perturbation of AKT activity. Indeed, while as previously reported pThr308AKT1 phosphorylation, reflecting activity, 35 progressively decreased with the severity of liver histology, 15, 27 there was a specular trend for upregulation, or at least preserved activation of AKT2. It could be speculated that this differential regulation of AKT isoforms, which might be related to specificities of protein-protein interaction, recruitment of coactivators or subcellular compartmentalization, brings about the divergent effects of insulin on glucose and lipid metabolism, but demonstration of specific signaling of IRS2 towards AKT2 is presently lacking. However, AKT2 is required for hepatic lipid accumulation in mouse models of IR, as liver-specific AKT2 knockout mice failed to develop steatosis because of a reduction of DNL mediated by SREBP1c. 9, 10, 19 Others found that, both in a mouse model of obesity and diabetes and in vitro in hepatocytes, selective downregulation of pSer473AKT, with preserved pThr308AKT levels, may explain selective inhibition of insulin signaling. 36 However, specific phosphorylation of AKT1 and AKT2, as well as IRS1 and IRS2 expression, were not analyzed. It is therefore possible that the preserved pThr308AKT levels may result from average pAKT1 (increased) and pAKT2 levels (decreased). Alternatively, the regulation may be species specific. Indeed, in line with previous findings, 27 we also observed downregulation of pThr308AKT1 in obese patients with NASH, whereas the progressive decrease of pSer473AKT1 was less marked and not significant. It is therefore unlikely that preserved activation of AKT1 at Thr308 explain increased lipogenesis in severely obese patients with NASH.
Coherently with these previous findings, increased AKT2 activity with steatosis was mirrored by SREBP1c mRNA and protein levels in the liver of obese patients, and by a parallel increase of its target GCK. 21 Furthermore, gene expression of GCK was correlated with the expression of DNL enzymes. The increased availability of saccharides would stimulate glycolysis and the pentose phosphate pathway, with increased availability of acetyl-CoA and NADPH for lipid synthesis. 37 Interestingly, glucose-6-phosphate has been proposed as metabolite signal for FAS transcription, 38, 39 and FAS and SCD1 require both elevated insulin and glucose levels to be fully expressed in liver. 40, 41 A major role of GCK induction in the pathogenesis of steatosis is corroborated by the evidence that dietary fructose intake and that a polymorphism in GCK regulatory protein determining reduced inhibition by the substrate fructose-6-phosphate are major risk factors for NAFLD. 42 Thus, it seems that signals resulting from both IR (FOXO1 induced by decreased AKT1) 15, 27 and enhanced insulin signaling (SREBP1c associated with increased IRS2 and preserved AKT2) 43 converge on GCK providing substrates for DNL. In contrast, we did not observe differential unfolded protein response activation, possibly influencing SREBP1c induction, according to liver histology. These results may be explained by the fact that all the individuals analyzed were severely obese, and therefore exposed to stressors stimulating the induction of the endoplasmic reticulum stress response independently of the severity of hepatic inflammation.
The metabolic imbalance between DNL and b-oxidation and lipoprotein export is another possible mechanism contributing to hepatic fat accumulation. Impaired b-oxidation was confirmed by significant reduction of PPARa expression and SREBP1c/PPAR-a mRNA content ratio, 24 which has been correlated with both homeostasis model of assessment and serum insulin levels, in NASH patients. Also, downregulation of MTTP, which notably is negatively regulated by FOXO1, 25 was associated with steatosis in the present series.
This study suffers from inherent limitations related to the evaluation of human samples, including inter-individual variability, with genetic and environmental unmeasured confounders, the small amount of starting material limiting analyses and the lack of IRS2 and steatosis R Rametta et al possibility to investigate causal relationships. The other side of the medal is related to the possibility to catch a glimpse of the metabolic picture in obese patients, which could help to frame previous studies in animal models, and to give a preliminary overview to elucidate the mechanisms underpinning the dual response of the steatosic liver to insulin.
In conclusion, we report a differential regulation of IRS1 and IRS2 and of their downstream effectors AKT1 and AKT2 in severely obese patients with steatosis, which may justify the paradoxical state of IR on glucoregulatory pathway and augmented insulin sensitivity of liporegulatory pathway typical of NAFLD. According to this model (Figure 2) , reduced AKT1-mediated inhibition of FOXO1 due to IR would increase HGO, inhibit lipoprotein export and upregulate IRS2. IRS2 would transduce insulin signal through AKT2 on SREBP1c, supporting DNL. The FOXO1 and SREBP1c pathways would further converge on upregulation of GCK providing substrates for DNL. Further studies are required to assess the possible mechanism of interaction and regulation of DNL and hepatic lipid metabolism by IRS2 and AKT2 signaling in experimental models. Figure 2 . Schematic representation of the hypothesized mechanisms of selective post-receptor hepatic insulin resistance based on the results of this study. The insulin-resistant glucoregulatory pathway is represented by red arrows. IRS1 fails to transduce impaired insulin signal through downregulation of AKT1 activity on FOXO1, preventing FOXO1 phosphorylation and nuclear exclusion, which results in unblunted gluconeogenesis. Glucose accumulation and FOXO1/SREBP1c activation lead to upregulation of GCK, which provides glucose-6-phosphate to DNL. Green arrows represent insulin-sensitive liporegulatory pathway. Upregulated IRS2 transduces insulin signals, possibly through upregulation of AKT2 activity (dashed line), on SREBP1C inducing upregulation of DNL and GCK. Yellow arrows shows increased DNL and impaired FA b-oxidation and FA export. pT308AKT1, murine thymome viral oncogene homolog 1 phosphorylated at threonine 308; AKT2, murine thymome viral oncogene homolog 2 phosphorylated at threonine 308; pS256FOXO1, Forkhead Transcription Factor1 phosphorylated at serine 256; SREBP1c, sterol regulatory element-binding protein 1c; GCK, glucokinase; Glucose 6P, glucose-6-phosphate.
